(1) Chengying Xie#, Huajun Zhao#, Xubin Bao, Haoyu Fu, and Liguang Lou*. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med. 2018; 22(11):5367-5377.
(2) Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, and Liguang Lou*. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207-1219.
(3) Chengying Xie, Xiangling Chen, Mingyue Zheng, Xiaohong Liu, Hongbin Wang, and Liguang Lou*. Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Oncotarget. 2017; 8(64):107977-107990.
(4) Chengying Xie, Ye He, Mingyue Zheng, Yulan Wang,Yongping Xu, and Liguang Lou. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer Sci. 2017;108(7):1476-1484.
(5) Xiangling Chen, Peng Liu, Quanren Wang, Yun Li, Li Fu, Haoyu Fu, Jianming Zhu, Zhaoqiang Chen, Weiliang Zhu*, Chengying Xie*, and Liguang Lou*. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction. Cancer Lett. 2018;434: 70-80.
(6) Ye He, Liping Sun, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Chengying Xie*, and Liguang Lou*. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia. Cancer Lett. 2018;420: 49-59.
(7) Zhihui Zhu, Chenghua Lou, Zhiguo Zheng, Rui Zhu, Shasha Tian, Chengying Xie*, and Huajun Zhao*. ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer. Gynecol Oncol. 2017; 174(2):418-425.
(8) Mingzhao Gao, Hongbin Wang, Xiangling Chen, Wenting Cao, Li Fu, Yun Li, Hatian Quan, Chengying Xie*, and Liguang Lou*. Aberrant modulation of riosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Acta Pharmacol Sin. 2018;18.doi: 10.1038／s41401-018-0020-z. [Epub ahead of print]
(9) Zhixin Zhao, Jianming Zhu, Haitian Quan, Guimin Wang, Bo Li, Weiliang Zhu*, Chengying Xie*, and Liguang Lou*. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response. Oncotarget. 2016;7(20):29648-29663. |
